View More

Morning Walk has successfully achieved CE Marking under the European Medical Device Regulation

Curexo's gait rehabilitation robot Morning Walk has obtained CE Marking under the European Medical Device Regulation (MDR). Compared to the previous Medical Device Directive (MDD), the MDR significantly strengthens safety and quality requirements. With this certification, Curexo has secured a foundation for entering the European rehabilitation robotics market. Based on this milestone, the company plans to actively expand into the global rehabilitation robotics market, including Europe, the Middle East, and Africa.

View More

Participation in AAOS 2026, the largest orthopedic conference in the United States

Curexo participated in AAOS 2026, the largest orthopedic conference in North America, held in New Orleans, United States.At the event, Curexo showcased its robotic systems for joint replacement surgery, CUVIS-joint and CUVIS-joint THA, designed for hip arthroplasty. The company also introduced its AI-powered robotic surgery platform featuring AI-bone Segmentation, an AI-based automatic bone segmentation technology. Through the exhibition, Curexo expanded engagement with North American surgeons and industry professionals, further strengthening the foundation for its global market expansion.

View More

Participation in ITC (International Trauma Congress) 2026, Dubai

Curexo participated in the ITC (International Trauma Congress) held in Dubai from the 13th to the 15th. At the exhibition, Curexo introduced its robotic system for joint replacement surgery, CUVIS-joint, together with its Egyptian partner Orthohouse, aiming to expand its sales network across the Middle East and North Africa (MENA) market. Curexo continues to pursue market expansion through a global partnership–based strategy, engaging with local medical professionals and distributors in the region.

View More

Participates in WHX Dubai 2026, Accelerates Middle East Med-Robotics Expansion

- Showcases CUVIS-joint Surgical Robot and Morning Walk Rehabilitation Robot, Expands Middle East Network Medical robotics specialist Curexo (060280) announced on the 13th that it successfully participated in WHX Dubai 2026, the world's largest medical device exhibition, held from the 9th to the 12th in Dubai, UAE.Visitors listen to an explanation of the Morning Walk gait rehabilitation robot at the Curexo booth during WHX Dubai 2026. [Photo courtesy of Curexo]  WHX Dubai 2026 (World Health Expo Dubai) is a leading global healthcare exhibition representing the Middle East region, attracting medical device companies, healthcare professionals, and industry stakeholders from around the world. At the exhibition, Curexo showcased its flagship products: the CUVIS-joint robotic system for joint replacement surgery and the Morning Walk gait rehabilitation robot. During the exhibition, the company's booth received visits from medical device distributors and healthcare institution representatives across the Middle East and Africa. Based on live demonstrations, discussions were held regarding potential equipment adoption and partnership opportunities. Through these meetings, the company confirmed the potential for expanding its local partnership network in the Middle East. In particular, Curexo shared its global business roadmap, including its goal of obtaining CE MDR certification in Europe this year, further strengthening partner confidence. CE MDR certification represents enhanced safety and quality standards required not only in Europe but also in key overseas markets such as the Middle East. Securing the certification is expected to serve as a critical turning point for expanding global sales. A Curexo official stated, "The Middle East is a strategic market where government-led healthcare investment and demand for advanced medical services are rapidly increasing. Building on this exhibition, we will accelerate our expansion into the Middle East medical robotics market and further drive overseas revenue growth."

View More

Indian Subsidiary Secures Medical Device Import License, Expands Local Supply and Service

– Localization of Core Parts and Consumables Supply Chain … Establishment of Local Supply and After-Sales Service SystemCurexo Co., Ltd., a medical robotics company led by CEO Lee Jae-jun, announced on the 13th that its Indian subsidiary has obtained a Medical Device Import License (MD-15) from the Central Drugs Standard Control Organization (CDSCO) for its robotic joint surgery system, CUVIS-joint."CUVIS-joint" (Photo courtesy of Curexo) This approval is a mandatory requirement for the importation of medical devices into India and is significant in that it enables the local subsidiary to directly supply the robotic system, as well as related consumables and core components. With the acquisition of the license, Curexo has established a system under which its Indian subsidiary can directly import and manage consumables and key components, for which demand is increasing in line with the growing number of surgical procedures. This is expected to shorten delivery lead times for consumables in India, enhance inventory responsiveness, and ultimately improve the operational stability and convenience of robotic surgery programs at medical institutions. In addition, the local subsidiary will serve as a service hub, providing equipment maintenance and technical support to distributors and healthcare institutions. The company stated that establishing a localized response system that integrates parts supply and technical support will help enhance equipment uptime and customer satisfaction, thereby laying the groundwork for future revenue growth. A Curexo official commented that the acquisition of the import license is meaningful in that it provides a stable foundation for the Indian subsidiary to carry out local supply and service functions, adding that the company will continue to strengthen its local capabilities to enhance business stability in the Indian market.

View More

CUVIS-Joint THA Achieves Clinical Success in Hip Replacement Surgery in Korea

- Bumin Hospital President Dr. Yong-Chan Ha Performs Korea's First Successful Hip Replacement Using a Domestic Medical Robot - Indication Expanded from Knee to Hip, Demonstrating an Expandable Surgical Platform CUREXO, a medical robotics company led by CEO Jae-Jun Lee, announced on the 10th that it has successfully completed a total hip arthroplasty (THA) using CUVIS-Joint THA, marking the first successful clinical hip replacement performed by a Korean medical robotics company. The surgery was performed at Seoul Bumin Hospital by Dr. Yong-Chan Ha, President of the hospital and a nationally and internationally recognized authority in hip surgery. This procedure is particularly significant as it represents the first clinical success by a domestic medical robotics company for the THA indication using CUVIS-Joint."Dr. Yong-Chan Ha of Seoul Bumin Hospital is performing hip replacement surgery using Curexo's CUVIS-Joint THA." CUVIS-Joint THA establishes a three-dimensional preoperative surgical plan based on the patient's anatomical structure and enables highly precise bone resection through robotic assistance. This approach minimizes key variables in hip replacement surgery—such as implant positioning errors and leg length discrepancies—thereby maximizing surgical accuracy and consistency. CUREXO has already led the commercialization of domestically developed orthopedic surgical robots through CUVIS-Joint for knee replacement procedures. With this successful hip replacement surgery, the company has expanded its application from the knee to the hip. This achievement demonstrates that CUVIS-Joint is an expandable surgical platform capable of supporting multiple joint replacement procedures within a single robotic system. Dr. Ha stated, "This clinical case is highly meaningful in that it proves, through real-world practice, that Korean-developed surgical robots are capable of performing complex hip surgeries with a high level of precision. As surgical data continues to accumulate, CUVIS-Joint has the potential to drive transformative changes across the field of orthopedic surgery." A CUREXO representative added, "CUVIS-Joint THA is a solution designed to maximize precision in complex hip replacement procedures. Having demonstrated our robotic capabilities in both knee and hip surgeries, we will continue striving to become a global leader in the orthopedic surgical robotics market."

View More

CUREXO Hosts Global Webinar on Gait Rehabilitation Robot 'MorningWalk'

• Sharing rehabilitation research outcomes with Seoul National University, Charité – Universitätsmedizin Berlin and UTMB• Presenting advanced rehabilitation solutions integrating BCI and VR technologies Medical robot specialist CUREXO Inc. (CEO: Jae Jun Lee) announced that it held a global webinar on the 17th to share domestic and international research outcomes related to its gait rehabilitation robot system, MorningWalk. The webinar, d "MorningWalk: Redefining the Future of Gait Rehabilitation Robotics," was organized to discuss research trends and clinical applications in the field of robotic gait rehabilitation. The event brought together CUREXO researchers and experts in rehabilitation robotics from leading universities and medical institutions, including Seoul National University, Charité – Universitätsmedizin Berlin, and a Texas medical school. Participants presented on the future direction of robotic gait rehabilitation technology and its therapeutic effectiveness in real clinical settings. During the webinar, collaborative research cases were shared that integrate advanced technologies—such as brain-computer interfaces (BCI), soft wearable robots, and virtual reality (VR)-based propulsion force feedback training—with CUREXO's MorningWalk system. [Photo 1 = CUREXO] 2025 MorningWalk Webinar CUREXO 's MorningWalk is an end-effector–based gait rehabilitation robot that provides customized rehabilitation training for pediatric to adult patients with various conditions, including stroke, spinal cord injury, and Parkinson's disease. Notably, it features a seated body-weight support system that reduces patient setup time to under three minutes. The system also enhances training efficiency by simulating not only level-ground walking but also stairs and slopes, enabling diverse gait environments. A CUREXO representative stated, "This webinar was a meaningful opportunity to share domestic and international research cases utilizing MorningWalk and to confirm its clinical effectiveness in the field of robotic gait rehabilitation. We will continue to advance gait rehabilitation robot technology and expand clinical applications through collaboration with global medical professionals and researchers."

View More

CUREXO Turns Profitable in Q3 and Diversifies Global Medical Robot Revenue Base

• Cumulative sales of KRW 53.7 billion, up 30% year-on-year• Medical robot segment revenue up 80% year-on-year• Sales network expanded to Japan, Taiwan, Indonesia, Malaysia and PakistanSeoul, Republic of Korea – CUREXO Inc. (KOSDAQ: 060280), a medical robotics specialist, announced that it recorded an operating profit of KRW 9.7 billion on a consolidated basis in the third quarter, turning profitable compared with the same period last year.The company reported cumulative consolidated sales of KRW 53.7 billion for the first three quarters, representing a 30% increase year-on-year. In particular, cumulative revenue from its core medical robot business grew by 80% over the same period last year, driving both top-line growth and improved profitability.Operating profit for the third quarter came in at KRW 9.7 billion, marking a turnaround from both the prior-year quarter and the previous quarter and signaling a clear improvement in earnings quality.CUREXO explained that its performance was primarily supported by the diversification of its global medical robot sales portfolio. In 2024, the company expanded sales into new overseas markets including Japan, Taiwan, Indonesia, Malaysia and Pakistan, thereby broadening and stabilizing its international revenue base. The company also noted that sales in India, which were temporarily sluggish last year, have started to recover.A CUREXO spokesperson said,"Once we obtain regulatory approvals for CUVIS-joint in the United States (FDA), Europe (CE), and in markets such as the Middle East and Latin America, we expect to generate additional medical robot sales. We will continue to expand our presence in global markets and aim to maintain mid- to long-term growth momentum."

View More

CUREXO Secures Domestic Approval for Total Hip Arthroplasty (THA) Robot 'CUVIS-joint THA'

• Expansion of Indications from Knee to Hip Surgerical Robots… Enhanced Surgical Accuracy and Convenience with AI Medical robotics company CUREXO announced on the 2nd that it has obtained product approval from the Ministry of Food and Drug Safety (MFDS) for its total hip arthroplasty (THA) surgical robot, "CUVIS-joint THA." With this approval, CUREXO has expanded its product portfolio by adding hip indications to its existing knee joint replacement surgical robot, "CUVIS-joint." CUVIS-joint THA is equipped with AI-based automatic segmentation of hip CT images, surgical planning software, precision robotic control technology, and a user-friendly UI to enhance surgical convenience. (CUVIS-joint THA, photo = CUREXO) Based on this domestic approval, CUREXO plans to accelerate its global market entry by also pursuing overseas certifications, including the U.S. FDA and European CE approval for hip surgery. A CUREXO representative stated, "By integrating AI and robotic control technology, we have improved surgical accuracy and user convenience. We will continue to invest in R&D to strengthen our competitiveness in the global surgical robot market."